drugset / Trial / NCT00835588

Pantoprazole Sodium 40 mg DR Tablets Under Fasting Conditions

NCT00835588

Phase 1 Completed 100 enrolled Teva Pharmaceuticals USA
RandomizedCrossoverOpen-labelOther

Summary

The objective of this study is to compare the relative bioavailability of pantoprazole sodium 40 mg delayed-release tablets ( manufactured by TEVA Pharmaceuticals Industries, Ltd. and distributed by TEVA Pharmaceuticals USA) with that of PROTONIX® 40 mg delayed-released tablets (Wyeth-Ayerst) in Healthy, adult, non-smoking subjects under fasting conditions.

Timeline

Start
2003-12
Primary completion
2003-12
Completion
2003-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Pantoprazole Other / unclassified 40 mg

Indications

No indication recorded.